Could cause temporary or reversible harm; serious harm is unlikely.
Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .
| Brand name | TELMISARTAN AND HYDROCHLOROTHIAZIDE |
| Generic name | TELMISARTAN AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, TELMISARTAN |
| Distributed by / for | Glenmark Pharmaceuticals Inc, USA, Mahwah, NJ 07430 |
| NDC | 68462-842-13 |
| Full product label | Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/25 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc, USA, Mahwah, NJ 07430, NDC 68462-842-13. |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | nationwide |
| Quantity | 72288 units |
| Recall initiated | 2022-06-29 |
| Report date | 2022-08-17 |
| Recall completed | 2024-06-27 |
| Recall number | D-1305-2022 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Mahwah NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗